JP, IMO, once we have something "tangible" that
Post# of 30028
Posted On: 09/24/2014 10:59:38 PM
JP,
IMO, once we have something "tangible" that's when marketing/PR will really come into play. Which includes LymPro, MANF, ELTOP, one after another or so it will feel like.
That "could" be their strategy. No wasted bullets...
We do have quite a list of Tangibles on deck...
7. Is there already a marketing plan for the Lympro commercialization?
Our strategy parameters are in place, however we cannot disclose at this time
https://dl.dropboxusercontent.com/content_lin...B0a9e?dl=1
We entered into an agreement with Icon Central Laboratories that gives the Company access to a global distribution network for LymPro and positions us to begin marketing LymPro to the Research Use Only (RUO) in the fourth quarter – we began ‘soft marketing’ to pharma companies at the Alzheimer’s Association International Conference in July and can now definitively describe our path forward with Icon - See more at: http://www.thechairmansblog.com/amarantus-bio...jcPIS.dpuf
By the end of 2014 the Company anticipates:
Announcing data from our ongoing LP-002 clinical study
Completing the validation work at Icon to support LymPro’s launch
Submission of the package to CLIA to support commercial launch as an LDT
Announcing data for MANF in an undisclosed orphan indication at Targeting Ocular Disorders on October 6th, 2014 in Boston
Filing an orphan drug designation application with the FDA for MANF in Retinitis Pigmentosa and immediately thereafter will be submitting a second ocular orphan drug application for MANF with the FDA
Initiating GMP manufacturing for MANF to support first-in-man clinical trials
Additional data from ongoing MANF ocular studies
Data from studies with Renishaw related to MANF’s Convection Enhanced Delivery use for Parkinson’s disease
Submit request for Pre-IND meeting with the FDA for Eltoprazine next week
Receive Feedback from the FDA on our proposed PD LID trial design (of note, based on a further analysis of the data we expect the trial to be significantly less than 200 patients) and finalize the trial design
Submit the IND to the FDA for Eltporazine
Potentially have the first patient in potential Eltporazine trial for PD LID (due to the holidays this could end up being very early in 2015) in or around the JP Morgan Healthcare Conference - See more at: http://www.thechairmansblog.com/amarantus-bio...iLepO.dpuf
And of course...
http://investorshangout.com/post/view?id=1999056
IMO, once we have something "tangible" that's when marketing/PR will really come into play. Which includes LymPro, MANF, ELTOP, one after another or so it will feel like.
That "could" be their strategy. No wasted bullets...
We do have quite a list of Tangibles on deck...
7. Is there already a marketing plan for the Lympro commercialization?
Our strategy parameters are in place, however we cannot disclose at this time
https://dl.dropboxusercontent.com/content_lin...B0a9e?dl=1
We entered into an agreement with Icon Central Laboratories that gives the Company access to a global distribution network for LymPro and positions us to begin marketing LymPro to the Research Use Only (RUO) in the fourth quarter – we began ‘soft marketing’ to pharma companies at the Alzheimer’s Association International Conference in July and can now definitively describe our path forward with Icon - See more at: http://www.thechairmansblog.com/amarantus-bio...jcPIS.dpuf
By the end of 2014 the Company anticipates:
Announcing data from our ongoing LP-002 clinical study
Completing the validation work at Icon to support LymPro’s launch
Submission of the package to CLIA to support commercial launch as an LDT
Announcing data for MANF in an undisclosed orphan indication at Targeting Ocular Disorders on October 6th, 2014 in Boston
Filing an orphan drug designation application with the FDA for MANF in Retinitis Pigmentosa and immediately thereafter will be submitting a second ocular orphan drug application for MANF with the FDA
Initiating GMP manufacturing for MANF to support first-in-man clinical trials
Additional data from ongoing MANF ocular studies
Data from studies with Renishaw related to MANF’s Convection Enhanced Delivery use for Parkinson’s disease
Submit request for Pre-IND meeting with the FDA for Eltoprazine next week
Receive Feedback from the FDA on our proposed PD LID trial design (of note, based on a further analysis of the data we expect the trial to be significantly less than 200 patients) and finalize the trial design
Submit the IND to the FDA for Eltporazine
Potentially have the first patient in potential Eltporazine trial for PD LID (due to the holidays this could end up being very early in 2015) in or around the JP Morgan Healthcare Conference - See more at: http://www.thechairmansblog.com/amarantus-bio...iLepO.dpuf
And of course...
http://investorshangout.com/post/view?id=1999056
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼